This federal Project Grant award to Virginia Commonwealth University (VCU), under the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395), provides $503,685 to evaluate a novel therapeutic agent called PEPDG278D for overcoming drug resistance in non-small cell lung cancer (NSCLC). The project aims to determine if PEPDG278D can effectively degrade the oncogenic proteins EGFR and HER2, including mutant forms, to inhibit NSCLC cell and tumor growth that is resistant to current EGFR inhibitors like osimertinib and necitumumab. The 5-year research effort, commencing July 2024, will assess PEPDG278D's ability to block oncogenic signaling and induce antitumor activity in NSCLC models expressing wild-type and mutant EGFR/HER2. The project also seeks to determine if PEPDG278D can effectively treat osimertinib-resistant NSCLC, either as a monotherapy or in combination.
Generated 3/4/25, 4:32 AM